Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Hepatocellular Carcinoma Treatment and Prognosis
TopicLeading institutions, researchers & key papers
This cluster of papers focuses on the management, diagnosis, and treatment of hepatocellular carcinoma (HCC), also known as liver cancer. It covers various aspects including clinical practice guidelines, radiofrequency ablation, use of sorafenib, liver resection, and survival rates.
805
Works
IDs:OpenAlex
How has Hepatocellular Carcinoma Treatment and Prognosis's publication output changed over time?
ScholarIQpublication output · 2008–2021
Output grew0% over the shown period — from 1 works in 2008 to 1 in 2021.
1
2
2
1
1
2
2
1
1
1
2008200920102011201420152017201820192021
What are the most-cited papers on Hepatocellular Carcinoma Treatment and Prognosis?
ScholarIQmost cited works
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach, Laura Kulik, Richard S. Finn, Claude B. Sirlin, Michaël Abécassis, Lewis R. Roberts, Andrew X. Zhu, M. Hassan Murad, Jorge A. Marrero
S156174673. 20174,185 CitationsOPEN ACCESS
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar, Jamil Asselah, Jean‐Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita
The Lancet Oncology. 20182,547 Citations
Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS)
Nuh N. Rahbari, O. James Garden, Robert Padbury, Mark E. Brooke‐Smith, Michael Crawford, René Adam, Moritz Koch, Masatoshi Makuuchi, Ronald P. DeMatteo, Christopher Christophi, Simon Banting, Val Usatoff, Masato Nagino, Guy J. Maddern, Thomas J. Hugh, Jean‐Nicolas Vauthey, Paul D. Greig, Myrddin Rees, Yukihiro Yokoyama, Sheung Tat Fan, Yuji Nimura, Joan Figueras, Lorenzo Capussotti, Markus W. Büchler, Jürgen Weitz
Surgery. 20112,300 Citations
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata, Ann‐Lii Cheng, Norihiro Kokudo, Masatoshi Kudo, Jeong Min Lee, Jidong Jia, Ryosuke Tateishi, Kwang‐Hyub Han, Yoghesh K. Chawla, Shuichiro Shiina, Wasim Jafri, Diana A. Payawal, Takamasa Ohki, Sadahisa Ogasawara, Pei‐Jer Chen, Cosmas Rinaldi Adithya Lesmana, Laurentius A. Lesmana, Rino Alvani Gani, Shuntaro Obi, A. Kadir Dökmeci, Shiv Kumar Sarin
S94180312. 20172,193 CitationsOPEN ACCESS
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
Vincenzo Mazzaferro, Josep M. Llovet, Rosalba Miceli, Sherrie Bhoori, Marcello Schiavo, Luigi Mariani, Tiziana Camerini, Sasan Roayaie, Myron Schwartz, Gian Luca Grazi, René Adam, P. Neuhaus, Mauro Salizzoni, Jordi Bruix, Alejandro Forner, Luciano De Carlis, Umberto Cillo, Andrew K. Burroughs, Roberto Troisi, Massimo Rossi, Giorgio Enrico Gerunda, Jan Lerut, Jacques Belghiti, I. Boin, Jean Gugenheim, Fedja A. Rochling, Bart van Hoek, Pietro Majno
The Lancet Oncology. 20082,043 CitationsOPEN ACCESS
Where is Hepatocellular Carcinoma Treatment and Prognosis research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Hepatocellular Carcinoma Treatment and Prognosis is open access?
ScholarIQopen access share
60%OPEN ACCESS
Gold
0%
Green
13%
Hybrid
33%
Bronze
13%
Closed
40%
Related on ScholarIQ
AASLD guidelines for the treatment of hepatocellular carcinoma
Paper
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Paper
Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS)
Paper
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Paper
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
Paper
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Paper